Clinical trial
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally…
NCT00331955 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00331955 |
|---|---|
| Title | Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors |
| Official title | Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | doxorubicin hydrochloride, vorinostat, pharmacological study, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2012 |
| First posted | May 31, 2006 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: